Efficacy of tofacitinib in psoriatic arthritis: literature review and case report

The article presents the results of a search in the PubMed and Google Scholar databases (meta-analyses, systematic reviews, clinical trials and case studies) evaluating the treatment of PsA with tofacitinib (TOFA). The review contains the most up-to-date information about the efficacy and safety of TOFA, a drug from the group of janus kinase inhibitors (JAKi), a brief description of the mechanism of action of TOFA is given, with mention of blocked signaling intracellular pathways. The spectrum of “key” clinical manifestations of psoriatic arthritis (PsA) is described, in which the therapeutic potential of TOFA (peripheral arthritis, psoriasis, enthesitis and dactylitis) is most fully revealed. The results of the main randomized controlled trials (OPAL Broaden and OPAL Beyond), postmarketing trials, descriptive studies and clinical observations are considered, and the high efficacy of TOFA for the treatment of PsA patients who did not respond to therapy with synthetic disease-modifying drugs and/ or Tumor Necrosis Factor inhibitors (TNFi) is demonstrated. The results (and their interpretation) of studying the safety of long-term use of different doses of TOFA – 5 mg 2 times a day and 10 mg 2 times a day and retention (“survival”) are presented therapy, with an emphasis on adverse events of special interest (“large” cardiological events (MACE), oncologics, infections). The results of treatment with tofacitinib in patients with PsA according to the All-Russian register of patients are presented. The pronounced positive effect of TOFA on the parameters that are defined as “patient-reported outcome – PRO” is particularly emphasized: indicators of fatigue, self-assessment, patient’s assessment of his condition according to VAS, assessment by HAQ-DI (Health Assessment Questionnaire), SF-36 (non-specific questionnaire for quality assessment patient’s life), etc. A clinical observation is presented that demonstrates a vivid therapeutic effect on arthritis, enteritis, dactylitis, clinical signs of spondylitis, sacroiliitis, as well as the skin process in a patient with active PsA.

1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–139. https://doi.org/10.1046/j.1087-0024.2003.09102.x.

2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–ii17. https://doi.org/10.1136/ard.2004.032482.

3. Mahler R, Jackson C, Ijacu H. The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. J Cutan Med Surg. 2009;13(6):283–293. https://doi.org/10.2310/7750.2009.08083.

4. Strober B, Karki C, Mason M, Guo N, Holmgren SH, Greenberg JD, Lebwohl M. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323–332. https://doi.org/10.1016/j.jaad.2017.10.012.

5. Kaine J, Song X, Kim G, Hur P, Palmer JB. Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data. J Manag Care Spec Pharm. 2019;25(1):122–132. https://doi.org/10.18553/jmcp.2018.17421.

6. Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I). Rheumatology Science and Practice. 2020;58(1):62–79. (In Russ.) https://doi.org/10.14412/1995-4484-2020-62-79.

7. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243. https://doi.org/10.4049/jimmunol.1003668.

8. Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017;377(16):1537–1550. https://doi.org/10.1056/NEJMoa1615975.

9. Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377(16):1525–1536. https://doi.org/10.1056/NEJMoa1615977.

10. Padda IS, Bhatt R, Parmar M. Tofacitinib. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK572148/.

11. van der Togt CJT, Verhoef LM, van den Bemt BJF, den Broeder N, Ter Heine R, den Broeder AA. Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study). Ther Adv Musculoskelet Dis. 2022;14:1759720X22 1142277. https://doi.org/10.1177/1759720X221142277.

12. Кубанов АА, Насонов ЕЛ, Бакулев АЛ, Знаменская ЛФ, Карамова АЭ, Коротаева ТВ и др. Псориаз артропатический. Псориатический артрит: клинические рекомендации. М.; 2021. Режим доступа: https://cr.minzdrav.gov.ru/schema/562_2.

13. Chichasova NV, Lila AM. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: results of 10 years of use. Meditsinskiy Sovet. 2022;16(21):139–145. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-21-139-145.

14. Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib for immunemediated inflammatory rheumatic diseases (PART II). Rheumatology Science and Practice. 2020;58(2):214–224. (In Russ.) https://doi.org/10.14412/1995-4484-2020-214-224.

15. Leng X, Lin W, Liu S, Kanik K, Wang C, Wan W et al. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. 2023;9(1):e002559. https://doi.org/10.1136/rmdopen-2022-002559.

16. Yang V, Kragstrup TW, McMaster C, Reid P, Singh N, Haysen SR et al. Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023. https://doi.org/10.1007/s40264-023-01333-0.

17. Eder L, Gladman DD, Mease P, Pollock RA, Luna R, Aydin SZ et al. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023;9(1):e002718. https://doi.org/10.1136/rmdopen-2022-002718.

18. Coates LC, Bushmakin AG, FitzGerald O, Gladman DD, Fallon L, Cappelleri JC et al. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. Arthritis Res Ther. 2021;23(1):94. https://doi.org/10.1186/s13075-021-02474-2.

19. Glintborg B, Di Giuseppe D, Wallman JK, Nordström DC, Gudbjornsson B, Hetland ML et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. 2023;82(6):820–828. https://doi.org/10.1136/ard-2022-223650.

20. Loginova EYu, Korotaeva TV, Gubar EE, Korsakova YuL, Glukhova SI, Vasilenko EA et al. Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis. Sovremennaya Revmatologiya. 2021;15(3):35–42. (In Russ.) https://doi.org/10.14412/1996-7012-2021-3-35-42.

21. Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489–2498. https://doi.org/10.1016/S0140-6736(15)00347-5.

22. Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC et al. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Res Ther. 2022;24(1):40. https://doi.org/10.1186/s13075-022-02721-0.

23. Merola JF, Shrom D, Eaton J, Dworkin C, Krebsbach C, Shah-Manek B, Birt J. Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey. Rheumatol Ther. 2019;6(1):33–45. https://doi.org/10.1007/s40744-018-0135-1.

24. Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G. Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. J Dermatolog Treat. 2022;33(5):2614–2620. https://doi.org/10.1080/09546634.2022.2060924.

25. Schneeberger EE, Citera G, Nash P, Smolen JS, Mease PJ, Soriano ER et al. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies. Semin Arthritis Rheum. 2023;58:152134. https://doi.org/10.1016/j.semarthrit.2022.152134.

26. Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004–1013. https://doi.org/10.1136/annrheumdis-2020-219601.

27. Proft F, Torgutalp M, Muche B, Rios Rodriguez V, Verba M, Poddubnyy D. Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial. BMJ Open. 2021;11(11):e048647. https://doi.org/10.1136/bmjopen-2021-048647.

28. Gubar EE, Korsakova YuL, Loginova EYu, Smirnov AV, Glukhova SI, Korotaeva TV. Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients. Rheumatology Science and Practice. 2021;59(2):134–140. (In Russ.) https://doi.org/10.47360/1995-4484-2021-134-140.

29. Jubber A, Tahir H, Moorthy A. Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: A scoping literature review. Musculoskeletal Care. 2023. https://doi.org/10.1002/msc.1802.

30. Mease PJ, Orbai AM, FitzGerald O, Bedaiwi M, Fleishaker DL, Mundayat R et al. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies. Arthritis Res Ther. 2023;25(1):153. https://doi.org/10.1186/s13075-023-03108-5.

31. Orbai AM, Mease PJ, Helliwell PS, FitzGerald O, Fleishaker DL, Mundayat R, Young P. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. BMC Rheumatol. 2022;6(1):68. https://doi.org/10.1186/s41927-022-00298-4.

32. de Vlam K, Mease PJ, Bushmakin AG, Fleischmann R, Ogdie A, Azevedo VF et al. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis. Rheumatol Ther. 2022;9(5):1451–1464. https://doi.org/10.1007/s40744-022-00482-5.

33. Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S et al. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022;8(2):e002478. https://doi.org/10.1136/rmdopen-2022-002478.

34. Harkins P, Burke E, Swales C, Silman A, Conway R. Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis. Int J Rheum Dis. 2023;26(1):31–42. https://doi.org/10.1111/1756-185X.14447.

35. Badokin VV. Psoriaticheskiy artrit (klinika, diagnostika, lechenie). Rheumatology Science and Practice. 2006;44(2s):65–77. (In Russ.) https://doi.org/10.14412/1995-4484-2006-1433.

36. Xue H, Ci X, Luo M, Wu L, Du X, Li L, Lu X. Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review. Clin Rheumatol. 2022;41(7):2225–2231. https://doi.org/10.1007/s10067-022-06113-2.

37. Gridneva GI, Aronova ES, Belov BS. Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data). Sovremennaya Revmatologiya. 2022;16(6):32–37. (In Russ.) https://doi.org/10.14412/1996-7012-2022-6-32-37.

38. Egeberg A, Rosenø NAL, Aagaard D, Lørup EH, Nielsen ML, Nymand L et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. https://doi.org/10.1016/j.semarthrit.2022.151979.

39. Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82(1):119–129. https://doi.org/10.1136/ard-2022-222259.

40. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071. https://doi.org/10.1002/art.39573.

41. Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(1):29–37. https://doi.org/10.1016/j.semarthrit.2017.02.001.

42. Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331–343. https://doi.org/ 10.1136/ard-2022-222543.

43. Balanescu AR, Citera G, Pascual-Ramos V, Bhatt DL, Connell CA, Gold D et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022;81(11):1491–1503. https://doi.org/10.1136/ard-2022-222405.

44. Burmester GR, Coates LC, Cohen SB, Tanaka Y, Vranic I, Nagy E et al. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Rheumatol Ther. 2023;10(5):1255–1276. https://doi.org/10.1007/s40744-023-00576-8.

45. Kristensen LE, Strober B, Poddubnyy D, Leung YY, Jo H, Kwok K et al. et al. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Ther Adv Musculoskelet Dis. 2023;15:1759720X221149965. https://doi.org/10.1177/1759720X221149965.

46. Elmariah SB, Smith JS, Merola JF. JAK in the (Black) Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety. Am J Clin Dermatol. 2022;23(4):427–431. https://doi.org/10.1007/s40257-022-00701-3.

47. Kleinrensink NJ, Perton FT, Pouw JN, Vincken NLA, Hartgring SAY, Jansen MP et al. TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA). BMJ Open. 2022;12(10):e064338. https://doi.org/10.1136/bmjopen-2022-064338.